45 related articles for article (PubMed ID: 1873503)
1. Construction of reshaped human antibodies with HIV-neutralizing activity.
Maeda H; Matsushita S; Eda Y; Kimachi K; Tokiyoshi S; Bendig MM
Hum Antibodies Hybridomas; 1991 Jul; 2(3):124-34. PubMed ID: 1873503
[TBL] [Abstract][Full Text] [Related]
2. Construction and characterization of chimeric and humanized forms of a broadly neutralizing monoclonal antibody to HIV-1.
Major JG; Liou RS; Sun LK; Yu LM; Starnes SM; Fung MS; Chang TW; Chang NT
Hum Antibodies Hybridomas; 1994; 5(1-2):9-17. PubMed ID: 7858187
[TBL] [Abstract][Full Text] [Related]
3. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
4. Anti-idiotypic antibodies to the third variable domain of gp120 induce an anti-HIV-1 antibody response in mice.
Boudet F; Theze J; Zouali M
Virology; 1994 Apr; 200(1):176-88. PubMed ID: 7510435
[TBL] [Abstract][Full Text] [Related]
5. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
[TBL] [Abstract][Full Text] [Related]
7. Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody.
Cavacini LA; Emes CL; Power J; Desharnais FD; Duval M; Montefiori D; Posner MR
J Immunol; 1995 Oct; 155(7):3638-44. PubMed ID: 7561063
[TBL] [Abstract][Full Text] [Related]
8. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.
Gorny MK; Xu JY; Karwowska S; Buchbinder A; Zolla-Pazner S
J Immunol; 1993 Jan; 150(2):635-43. PubMed ID: 7678279
[TBL] [Abstract][Full Text] [Related]
9. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
Back NK; Smit L; De Jong JJ; Keulen W; Schutten M; Goudsmit J; Tersmette M
Virology; 1994 Mar; 199(2):431-8. PubMed ID: 8122371
[TBL] [Abstract][Full Text] [Related]
10. Selection and characterization of an HIV-1 gp120-binding affibody ligand.
Wikman M; Rowcliffe E; Friedman M; Henning P; Lindholm L; Olofsson S; Ståhl S
Biotechnol Appl Biochem; 2006 Sep; 45(Pt 2):93-105. PubMed ID: 16712522
[TBL] [Abstract][Full Text] [Related]
11. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation.
Kettleborough CA; Saldanha J; Heath VJ; Morrison CJ; Bendig MM
Protein Eng; 1991 Oct; 4(7):773-83. PubMed ID: 1798701
[TBL] [Abstract][Full Text] [Related]
12. Design, expression, and characterization of a multivalent, combination HIV microbicide.
Sexton A; Harman S; Shattock RJ; Ma JK
FASEB J; 2009 Oct; 23(10):3590-600. PubMed ID: 19470798
[TBL] [Abstract][Full Text] [Related]
13. Virolysis and in vitro neutralization of HIV-1 by humanized monoclonal antibody hNM-01.
Nakamura M; Terada M; Sasaki H; Kamada M; Ohno T
Hybridoma; 2000 Dec; 19(6):427-34. PubMed ID: 11152394
[TBL] [Abstract][Full Text] [Related]
14. Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions.
Sato K; Tsuchiya M; Saldanha J; Koishihara Y; Ohsugi Y; Kishimoto T; Bendig MM
Mol Immunol; 1994 Apr; 31(5):371-81. PubMed ID: 8152440
[TBL] [Abstract][Full Text] [Related]
15. A humanized anti-tumor necrosis factor-alpha monoclonal antibody that acts as a partial, competitive antagonist of the template antibody.
Tempest PR; Barbanti E; Bremner P; Carr FJ; Ghislieri M; Rifaldi B; Marcucci F
Hybridoma; 1994 Jun; 13(3):183-90. PubMed ID: 7927362
[TBL] [Abstract][Full Text] [Related]
16. Efficient generation of a reshaped human mAb specific for the alpha toxin of Clostridium perfringens.
Tempest PR; White P; Williamson ED; Titball RW; Kelly DC; Kemp GJ; Gray PM; Forster SJ; Carr FJ; Harris WJ
Protein Eng; 1994 Dec; 7(12):1501-7. PubMed ID: 7716162
[TBL] [Abstract][Full Text] [Related]
17. [Construction and clinical application of chimeric antibodies].
Kuroki M; Arakawa F; Haruno M
Nihon Rinsho; 1995 Dec; 53(12):3122-31. PubMed ID: 8577069
[TBL] [Abstract][Full Text] [Related]
18. Human monoclonal antibodies: recent achievements.
Burton DR; Barbas CF
Hosp Pract (Off Ed); 1994 Nov; 29(11):111, 114-6, 119 passim. PubMed ID: 7962228
[TBL] [Abstract][Full Text] [Related]
19. A self shaped and reshaped: the statue within.
Stent GS
Science; 1988 Mar; 239(4847):1545-6. PubMed ID: 17772753
[No Abstract] [Full Text] [Related]
20. Preface How Molecular Genetics Has Reshaped Clinical Electrophysiology-From an Historical Perspective to the New Challenges.
Priori SG
Card Electrophysiol Clin; 2010 Dec; 2(4):xv-xvii. PubMed ID: 28770726
[No Abstract] [Full Text] [Related]
[Next] [New Search]
